INT55101

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 16
Disease Relevance 2.39
Pain Relevance 5.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Cst7)
Anatomy Link Frequency
nerve 2
digit 2
striated muscles 1
Cst7 (Mus musculus)
Pain Link Frequency Relevance Heat
Action potential 998 100.00 Very High Very High Very High
carpal tunnel syndrome 216 99.96 Very High Very High Very High
lidocaine 2 96.08 Very High Very High Very High
c fibre 25 82.48 Quite High
sodium channel 6 75.00 Quite High
hyperexcitability 25 67.48 Quite High
alcohol 2 53.20 Quite High
Quantitative sensory testing 5 52.72 Quite High
ischemia 32 44.72 Quite Low
cytokine 3 28.80 Quite Low
Disease Link Frequency Relevance Heat
Carpal Tunnel Syndrome 228 99.96 Very High Very High Very High
Sepsis 171 98.56 Very High Very High Very High
Handedness 2 89.28 High High
Injury 111 84.56 Quite High
Congenital Anomalies 8 74.52 Quite High
Systemic Inflammatory Response Syndrome 21 54.08 Quite High
Arrhythmias 2 Under Development 9 51.20 Quite High
Neuropathic Pain 53 50.00 Quite Low
Mycobacterium Infection 32 50.00 Quite Low
Drug Induced Neurotoxicity 11 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Repetitive CMAPs (Fig 2C) were present in most patients tested on days 2 to 4 after oxaliplatin (5 of 7; 71%) but in fewer patients tested before oxaliplatin (1 of 8; 13%), on days 14 to 20 after oxaliplatin (2 of 8; 25%) or on days 2 to 4 after carboplatin plus paclitaxel or cisplatin (1 of 6; 17%).
Gene_expression (present) of CMAP
1) Confidence 0.75 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2936328 Disease Relevance 0.07 Pain Relevance 0.03
The CMAP duration was also shorter when spontaneous EMG was recorded (0.989 vs 0.82 p < .01 t = -2.65, N = 3897) than when it was not.
Gene_expression (duration) of CMAP associated with action potential
2) Confidence 0.58 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0 Pain Relevance 0.40
In order to better elucidate the changes in the CMAP, figures 4 and 5 show the normalized CMAP velocity and CMAP duration respectively from each recorded potential as a function of the normalized CMAP amplitude.
Gene_expression (velocity) of CMAP associated with action potential
3) Confidence 0.58 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0 Pain Relevance 0.43
There is also no significant correlation between the CMAP amplitude reduction during the 1st compression and CMAP amplitude reduction during the final recovery.
Gene_expression (reduction) of CMAP associated with action potential
4) Confidence 0.58 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0 Pain Relevance 0.41
There is also no significant correlation between the CMAP amplitude reduction during the 1st compression and CMAP amplitude reduction during the final recovery.
Gene_expression (reduction) of CMAP associated with action potential
5) Confidence 0.58 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0 Pain Relevance 0.40
In order to better elucidate the changes in the CMAP, figures 4 and 5 show the normalized CMAP velocity and CMAP duration respectively from each recorded potential as a function of the normalized CMAP amplitude.
Gene_expression (duration) of CMAP associated with action potential
6) Confidence 0.58 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0 Pain Relevance 0.43
CMAP's were recorded continuously during the entire period

Statistical analysis

Gene_expression (recorded) of CMAP associated with action potential
7) Confidence 0.58 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0 Pain Relevance 0.18
The duration of the CMAP is measured as the difference between the time of the first and last noticeable deflection of the CMAP.
Gene_expression (duration) of CMAP associated with action potential
8) Confidence 0.58 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0 Pain Relevance 0.50
After recovery of the CMAP and SNAP amplitudes, nerve conduction velocity improved gradually over a period of 3-6 h, the amplitudes and configurations of CMAP and SNAP remaining unchanged.
Gene_expression (recovery) of CMAP in nerve associated with action potential
9) Confidence 0.56 Published 1994 Journal J. Neurol. Sci. Section Abstract Doc Link 7964875 Disease Relevance 0.05 Pain Relevance 0.89
This conclusion is also supported by the fact that larger axons are associated with larger motor units with longer durations so that loss of these larger axons should produce shorter duration CMAP's by this mechanism as well.
Gene_expression (produce) of CMAP associated with action potential
10) Confidence 0.52 Published 2008 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2245939 Disease Relevance 0.08 Pain Relevance 0.54
prolongation of both median motor (CMAP > 4.4 ms) and sensory distal latencies (median mid palmer latency > 2.2 ms or prolongation of the median mid-palmar CNAP relative to the ulnar mid-palmar CNAP > 0.4 ms or a difference in latency > 0.5 ms between median and ulnar SNAPs of digit four); with either an absent SNAP, or low amplitude thenar CMAP [4,17].


Gene_expression (prolongation) of CMAP in digit associated with action potential
11) Confidence 0.33 Published 2010 Journal J Neuroeng Rehabil Section Body Doc Link PMC2928769 Disease Relevance 0.47 Pain Relevance 0.47
prolongation of both median motor (CMAP > 4.4 ms) and sensory distal latencies (median mid palmer latency > 2.2 ms or prolongation of the median mid-palmar CNAP relative to the ulnar mid-palmar CNAP > 0.4 ms or a difference in latency > 0.5 ms between median and ulnar SNAPs of digit four); with either an absent SNAP, or low amplitude thenar CMAP [4,17].


Gene_expression (prolongation) of CMAP in digit associated with action potential
12) Confidence 0.33 Published 2010 Journal J Neuroeng Rehabil Section Body Doc Link PMC2928769 Disease Relevance 0.52 Pain Relevance 0.47
Statistically significant difference was found in CMAP duration only for session (F1,23 = 7.49, p = 0.012) but not for treatment (F1,23 = 4.02, p = 0.057) (p > 0.05) (Table 1).
Gene_expression (duration) of CMAP
13) Confidence 0.14 Published 2007 Journal Crit Care Section Body Doc Link PMC2151871 Disease Relevance 0.46 Pain Relevance 0
Our results indicate no change in CMAP duration but a decrease in amplitude and observable prolongation of the latency which is regarded as an indicator of axonal degeneration.
Gene_expression (duration) of CMAP associated with action potential
14) Confidence 0.14 Published 2007 Journal Crit Care Section Body Doc Link PMC2151871 Disease Relevance 0.44 Pain Relevance 0.22
CMAP is produced by synchronized activation of the muscle fibers after axonal innervations, which is the sum of the responses of the striated muscles to stimuli.
Gene_expression (produced) of CMAP in striated muscles associated with action potential
15) Confidence 0.12 Published 2007 Journal Crit Care Section Body Doc Link PMC2151871 Disease Relevance 0.28 Pain Relevance 0.25
Nerve conduction parameters, particularly SNAP amplitudes and CMAP velocities, were the most frequently affected measurements, followed by thermal thresholds, VPTs, MFs and, lastly, VMTs.
Gene_expression (velocities) of CMAP in Nerve associated with action potential
16) Confidence 0.03 Published 2008 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2270341 Disease Relevance 0 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox